TEL AVIV, Israel, May 6, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer
Management will discuss its proprietary stent platform technology: MGuard™, featuring a patent-pending micron mesh technology that wraps a stent, reducing Major Adverse Cardiac Events [MACE] by filtering debris and minimizing vessel injury by distributing strut pressure. MGuard™ has been implanted in thousands of patients with encouraging clinical results in Europe and Latin America. MGuard™ is a solution for high-risk Acute Coronary Syndrome (heart attack) patients — a market of over two million patients per year. The presentations will also discuss the Company's ongoing clinical efforts, including a randomized trial in Europe, Latin America and South Africa, chaired by Dr. Gregg Stone, to support its regulatory approval efforts, and its focus on securing FDA approval to sell its products in the U.S., including its collaboration with the Harvard Clinical Research Institute (HCRI), an international leader in design and conduct of coronary device trials, for U.S. FDA trials.
About The Benchmark Company, LLC
Headquartered in New York City, The Benchmark Company, LLC is an institutional brokerage firm with a strong sales/trading presence in addition to its rapidly expanding research and investment banking arms. In just nine years, Benchmark has established offices in 12 cities throughout the country.
About InspireMD Inc.
InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD is traded on the over-the-counter bulletin board (OTC BB) under the ticker "NSPR."
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payors for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Current Report on Form 8-K filed with the SEC on April 6, 2011. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumed no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Company Contact:www.inspire-md.comJonina OhayonMarketing Directorjonina@inspire-md.comOTC BB: NSPRInvestor Contact:Jeffrey StanlisPartner, Hayden IRjeff@haydenir.com(602) 476-1821
SOURCE InspireMD, Inc
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All